{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:37:43Z","timestamp":1784763463592,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12894-015-0117-3","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T22:04:49Z","timestamp":1451426689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Men under the age of 55\u00a0years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia"],"prefix":"10.1186","volume":"15","author":[{"given":"Nandu D.","family":"Dantanarayana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Hossack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warick","family":"Delprado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"117_CR1","first-page":"CD004720","volume":"1","author":"D Ilic","year":"2013","unstructured":"Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.","journal-title":"Cochrane Database Syst Rev"},{"key":"117_CR2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","volume":"190","author":"HB Carter","year":"2013","unstructured":"Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190:419\u201326.","journal-title":"J Urol"},{"key":"117_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.eururo.2011.05.006","volume":"60","author":"G Ploussard","year":"2011","unstructured":"Ploussard G, Epstein JI, Montironi R, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011;60:291\u2013303.","journal-title":"Eur Urol"},{"key":"117_CR4","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schroder","year":"2014","unstructured":"Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13\u00a0years of follow-up. Lancet. 2014;384:2027\u201335.","journal-title":"Lancet"},{"key":"117_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","volume":"104","author":"GL Andriole","year":"2012","unstructured":"Andriole GL, Crawford ED, Grubb 3rd RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13\u00a0years of follow-up. J Natl Cancer Inst. 2012;104:125\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"117_CR6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1464-410X.2011.09979.x","volume":"108","author":"SF Oon","year":"2011","unstructured":"Oon SF, Watson RW, O'Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int. 2011;108:518\u201325.","journal-title":"BJU Int"},{"key":"117_CR7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.urology.2007.08.055","volume":"70","author":"DJ Hernandez","year":"2007","unstructured":"Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology. 2007;70:931\u20135.","journal-title":"Urology"},{"key":"117_CR8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L","volume":"71","author":"TA Stamey","year":"1993","unstructured":"Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933\u20138.","journal-title":"Cancer"},{"key":"117_CR9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ijc.1260","volume":"92","author":"SE Oliver","year":"2001","unstructured":"Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the \u201cPSA ERA\u201d. Int J Cancer. 2001;92:893\u20138.","journal-title":"Int J Cancer"},{"key":"117_CR10","first-page":"3866","volume":"15","author":"GP Haas","year":"2008","unstructured":"Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866\u201371.","journal-title":"Can J Urol"},{"key":"117_CR11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","volume":"270","author":"JE Oesterling","year":"1993","unstructured":"Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860\u20134.","journal-title":"JAMA"},{"key":"117_CR12","first-page":"111","volume":"10","author":"A Stangelberger","year":"2008","unstructured":"Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10:111\u20139.","journal-title":"Rev Urol"},{"key":"117_CR13","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/cncr.24324","volume":"115","author":"DW Lin","year":"2009","unstructured":"Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009;115:2863\u201371.","journal-title":"Cancer"},{"key":"117_CR14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","volume":"11","author":"J Hugosson","year":"2010","unstructured":"Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725\u201332.","journal-title":"Lancet Oncol"},{"key":"117_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pros.20017","volume":"59","author":"F Labrie","year":"2004","unstructured":"Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311\u20138.","journal-title":"Prostate"},{"key":"117_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.urology.2005.01.049","volume":"66","author":"C Twiss","year":"2005","unstructured":"Twiss C, Slova D, Lepor H. Outcomes for men younger than 50\u00a0years undergoing radical prostatectomy. Urology. 2005;66:141\u20136.","journal-title":"Urology"},{"key":"117_CR17","first-page":"1603","volume":"169","author":"K Howard","year":"2009","unstructured":"Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med. 2009;169:1603\u201310.","journal-title":"Arch Intern Med"},{"key":"117_CR18","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","volume":"346","author":"AJ Vickers","year":"2013","unstructured":"Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.","journal-title":"BMJ"},{"key":"117_CR19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.25568","volume":"117","author":"H Lilja","year":"2011","unstructured":"Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30\u00a0years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117:1210\u20139.","journal-title":"Cancer"},{"key":"117_CR20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/cncr.10819","volume":"95","author":"K Hemminki","year":"2002","unstructured":"Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer. 2002;95:1346\u201353.","journal-title":"Cancer"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-015-0117-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T22:44:04Z","timestamp":1498257844000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2490\/15\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1186\/s12894-015-0117-3","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"124"}}